teceleukin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
interleukin-2 analogues and derivatives 5484 136279-32-8

Description:

MoleculeDescription

Molfile

Synonyms:

  • teceleukin
  • teceleukin (genetical recombination)
  • imunace
  • BG 8301
  • bioleukin
  • S-6820
a recombinant IL-2 product having a methionine added at the N-terminal.
  • Molecular weight: 15547.22
  • Formula: C698H1127N179O204S8
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA: 6216.69
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Dec. 31, 1992 PMDA SHIONOGI & Co., Ltd.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoalbuminaemia 150.17 76.23 32 601 15865 90611949
Aspartate aminotransferase increased 98.73 76.23 34 599 102903 90524911
Alanine aminotransferase increased 86.61 76.23 32 601 118306 90509508

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoalbuminaemia 108.40 62.84 29 685 15581 42605040
Aspartate aminotransferase increased 85.92 62.84 36 678 77127 42543494
Gamma-glutamyltransferase increased 75.53 62.84 26 688 32471 42588150
Alanine aminotransferase increased 65.38 62.84 31 683 88375 42532246
Pyrexia 63.42 62.84 52 662 393990 42226631

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoalbuminaemia 228.26 76.71 56 1315 28918 110559010
Aspartate aminotransferase increased 165.30 76.71 65 1306 159871 110428057
Alanine aminotransferase increased 136.46 76.71 59 1312 183714 110404214
Gamma-glutamyltransferase increased 123.86 76.71 41 1330 61268 110526660
Pyrexia 122.43 76.71 95 1276 898170 109689758
Face oedema 99.16 76.71 30 1341 33439 110554489
Platelet count decreased 77.05 76.71 43 1328 230400 110357528

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

None

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Enhancement of an antitumor effect of dinutuximab for neuroblastoma indication 432328008 DOID:769




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Interleukin-2 receptor Membrane receptor BINDING AGENT UNKNOWN KEGG DRUG

External reference:

IDSource
CHEBI:752934 CHEBI
CHEMBL2107892 ChEMBL_ID
DB15389 DRUGBANK_ID
D02749 KEGG_DRUG
C2825351 UMLSCUI
5838 INN_ID
65181 PUBCHEM_CID
H5ZRB188EI UNII

Pharmaceutical products:

None